Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results
|
HilleVax, Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
09/29/2023 |
SC 13G
| Deep Track Capital, LP reports a 6.1% stake in HilleVax, Inc. |
09/27/2023 |
SC 13D/A
| Frazier Life Sciences Public Fund, L.P. reports a 20.2% stake in HilleVax, Inc. |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results |
06/09/2023 |
4
| Chu Shelley (Director) has filed a Form 4 on HilleVax, Inc.
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
06/09/2023 |
4
| Cocero Nanette (Director) has filed a Form 4 on HilleVax, Inc.
Txns:
| Granted 11,000 options
@ $17.94, valued at
$197.3k
|
|
06/09/2023 |
4
| Gerberding Julie L. (Director) has filed a Form 4 on HilleVax, Inc.
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
06/09/2023 |
4
| Sepulveda Jaime (Director) has filed a Form 4 on HilleVax, Inc.
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
06/09/2023 |
4
| HILLEMAN JERYL L (Director) has filed a Form 4 on HilleVax, Inc.
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
06/09/2023 |
4
| Heron Patrick J (10% Owner) has filed a Form 4 on HilleVax, Inc.
Txns:
| Granted 22,500 options
@ $17.94, valued at
$403.7k
|
|
05/12/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/10/2023 |
4
| Cocero Nanette (Director) has filed a Form 4 on HilleVax, Inc.
Txns:
| Granted 34,000 options to buy
@ $14.2, valued at
$482.8k
|
|
05/10/2023 |
3
| Cocero Nanette (Director) has filed a Form 3 on HilleVax, Inc. |
05/10/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/25/2023 |
8-K
| Quarterly results |
04/18/2023 |
8-K
| Quarterly results |
03/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/17/2023 |
8-K
| Quarterly results |
02/14/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 5.3% stake in HILLEVAX, INC. |
02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/10/2023 |
SC 13G/A
| Flynn James E reports a 8.1% stake in HilleVax, Inc. |
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/10/2023 |
3
| Maltbie Shane (CFO) has filed a Form 3 on HilleVax, Inc. |
01/09/2023 |
8-K
| Investor presentation |
12/01/2022 |
4
| TAKEDA PHARMACEUTICAL CO LTD (10% Owner) has filed a Form 4 on HilleVax, Inc.
Txns:
| Exercised (in-or-at-the-money) 5,883,500 shares
@ $0 Exercised (in-or-at-the-money) 5,883,500 warrants
@ $0.0001, valued at
$588.4 |
|
|
|
|